Bloom Burton reiterated their accumulate rating on shares of Knight Therapeutics Inc (TSE:GUD) in a research note released on Thursday morning.

Other equities research analysts have also issued research reports about the company. CIBC upped their price target on Knight Therapeutics from C$9.50 to C$9.80 in a research report on Friday. TD Securities upped their target price on Knight Therapeutics from C$10.00 to C$11.00 and gave the company a buy rating in a research report on Friday. Finally, Scotiabank cut their target price on Knight Therapeutics from C$10.00 to C$9.50 and set an outperform rating on the stock in a research report on Friday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of Buy and an average price target of C$9.83.

Knight Therapeutics (TSE:GUD) opened at 9.64 on Thursday. Knight Therapeutics has a 1-year low of $5.89 and a 1-year high of $9.82. The firm has a 50-day moving average price of $9.19 and a 200-day moving average price of $8.63. The company has a market capitalization of $1.28 billion and a P/E ratio of 67.89.

About Knight Therapeutics

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.